INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 415m ago
HOUSE PTR15m ago
SEC 13F15m ago
ROBINHOOD CHAIN15m ago
SEC FORM 4/Grant or awardVerified data

Khan Bilal Arshad reported SGP

Director · SpyGlass Pharma, Inc. · SpyGlass Pharma, Inc. — Stock Option (right to buy)

Side
A
Value
—
Shares
13.7K
Price
—
Executed
Feb 5, 2026
Disclosed
Feb 9, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Feb 5 executedFeb 9, 2026 disclosed

SGP · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SGP

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    47
    KA
    Khan Bilal ArshadDirector
    SGPSpyGlass Pharma, Inc.
    Open-market purchase
    		BUY$320K
    20.0K sh
    		Feb 9, 2026Feb 11, 2026
    traded Feb 9, 2026
    		+2dSEC FORM 4

    Evidence

    50
    KA
    Khan Bilal ArshadDirector
    SGPSpyGlass Pharma, Inc.
    Open-market purchase
    		BUY$1.84M
    115.0K sh
    		Feb 9, 2026Feb 11, 2026
    traded Feb 9, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DR
    Dennewill James Robert Jr.Chief Operating Officer
    SGPSpyGlass Pharma, Inc.
    Grant or award
    		A—
    105.0K sh
    		Feb 5, 2026Feb 9, 2026
    traded Feb 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SZ
    Scheiner ZacharyDirector
    SGPSpyGlass Pharma, Inc.
    Grant or award
    		A—
    27.4K sh
    		Feb 5, 2026Feb 9, 2026
    traded Feb 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    MH
    Mooney Patrick H.Director, Chief Executive Officer
    SGPSpyGlass Pharma, Inc.
    Grant or award
    		A—
    300.0K sh
    		Feb 5, 2026Feb 9, 2026
    traded Feb 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    KY
    Kahook Malik Y.Director, See remarks
    SGPSpyGlass Pharma, Inc.
    Grant or award
    		A—
    105.0K sh
    		Feb 5, 2026Feb 9, 2026
    traded Feb 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    PP
    Pujara Chetan PratapChief R&D Officer
    SGPSpyGlass Pharma, Inc.
    Grant or award
    		A—
    105.0K sh
    		Feb 5, 2026Feb 9, 2026
    traded Feb 5, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002108044-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 5, 2026
    Published
    Feb 9, 2026
    Ingested by INSIDER
    Nov 5, 04:18 UTC
    Last re-read
    Nov 5, 04:18 UTC

    Extracted facts

    Filer
    Khan Bilal Arshad
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    SpyGlass Pharma, Inc. — Stock Option (right to buy)
    Ticker
    SGP
    Shares
    13.7K
    Price per share
    $0
    Execution date (reported)
    Feb 5, 2026
    Owned after transaction
    13.7K shares
    Days from execution to publication
    4

    What this establishes

    Khan Bilal Arshad filed this Form 4 reporting a grant or award of SGP on Feb 5, 2026. It became public on Feb 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Khan Bilal Arshadcik:0002108044
    Issuer
    SpyGlass Pharma, Inc.cik:0001778922

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.